ImmunityBio Inc [NASDAQ: IBRX] plunged by -$0.16 during the normal trading session on while it closed the day at $2.32.
ImmunityBio Inc stock has also loss -15.94% of its value over the past 7 days. However, IBRX stock has declined by -36.44% in the 3 months of the year. Over the past six months meanwhile, it has lost -63.52% and lost -9.38% year-on date.
The market cap for IBRX stock reached $1.69 billion, with 696.83 million shares outstanding and 75.93 million shares in the current float. Compared to the average trading volume of 6.84M shares, IBRX reached a trading volume of 6052308 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about ImmunityBio Inc [IBRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IBRX shares is $12.19 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IBRX stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BTIG Research have made an estimate for ImmunityBio Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 10, 2025. While these analysts kept the previous recommendation, Piper Sandler raised their target price from $10 to $4. The new note on the price target was released on May 12, 2023, representing the official price target for ImmunityBio Inc stock. Previously, the target price had yet another raise to $8, while Jefferies analysts kept a Buy rating on IBRX stock.
The Average True Range (ATR) for ImmunityBio Inc is set at 0.27, with the Price to Sales ratio for IBRX stock in the period of the last 12 months amounting to 231.10.
IBRX stock trade performance evaluation
ImmunityBio Inc [IBRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -15.94. With this latest performance, IBRX shares dropped by -26.35% in over the last four-week period, additionally sinking by -63.52% over the last 6 months – not to mention a drop of -41.56% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IBRX stock in for the last two-week period is set at 30.39, with the RSI for the last a single of trading hit 27.64, and the three-weeks RSI is set at 33.56 for ImmunityBio Inc [IBRX]. The present Moving Average for the last 50 days of trading for this stock 4.01, while it was recorded at 2.50 for the last single week of trading, and 5.02 for the last 200 days.
ImmunityBio Inc [IBRX]: An insightful look at the core fundamentals
ImmunityBio Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.64 and a Current Ratio set at 2.68.
ImmunityBio Inc [IBRX]: Institutional Ownership
There are presently around $9.62%, or 36.28%% of IBRX stock, in the hands of institutional investors. The top three institutional holders of IBRX stocks are: VANGUARD GROUP INC with ownership of 13.83 million shares, which is approximately 2.0558%. BLACKROCK INC., holding 11.42 million shares of the stock with an approximate value of $$72.19 million in IBRX stocks shares; and BLACKROCK INC., currently with $$49.7 million in IBRX stock with ownership which is approximately 1.1688%.
